Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Anticoagulation Among Patients Hospitalized for COVID-19 : A Systematic Review and Prospective Meta-analysis.
Ann Intern Med
January 2025
Background: Reported results of clinical trials assessing higher-dose anticoagulation in patients hospitalized for COVID-19 have been inconsistent.
Purpose: To estimate the association of higher- versus lower-dose anticoagulation with clinical outcomes.
Data Sources: Randomized trials were identified from the World Health Organization's International Clinical Trials Registry Platform and ClinicalTrials.
Whole exome sequencing reveals heparan sulfate proteoglycan 2 (HSPG2) as a potential causative gene for kidney stone disease in a Thai family.
Urolithiasis
December 2024
Siriraj Genomics, Office of the Dean, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
Kidney stone disease (KSD) is a prevalent and complex condition, with an incidence of 85 cases per 100,000 individuals in Thailand. Notably, over 40% of cases are concentrated in the northeastern region, indicating a potential genetic influence, which is supported by genetic mutations reported in several families by our research group. Despite this, the genetic basis of KSD remains largely unknown for many Thai families.
View Article and Find Full Text PDF[Rectal bleeding after positron emission tomography].
Rev Med Suisse
December 2024
Service de médecine nucléaire et d'imagerie moléculaire, Département de radiologie médicale, Centre hospitalier universitaire vaudois, 1011 Lausanne.
Article Synopsis
- A 60-year-old patient with cirrhosis from alcohol use is hospitalized due to stone cholangitis and undergoes an endoscopic procedure that leads to severe upper digestive bleeding.
- The patient's condition worsens with signs of bacteremia, raising concerns about potential endocarditis, prompting a PET-CT scan for further evaluation.
- After undergoing the PET-CT, the patient experiences rectal bleeding; during some PET-CT preparations, heparin is used to enhance imaging quality.
Bivalirudin vs Heparin Anticoagulation in STEMI: Confirmation of the BRIGHT-4 Results.
J Am Coll Cardiol
October 2024
Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; YNHH/ Yale Center for Outcomes Research and Evaluation (CORE), New Haven, Connecticut, USA.
Article Synopsis
- - The BRIGHT-4 study showed that using bivalirudin with a high-dose infusion after PCI led to lower overall mortality and bleeding risks compared to heparin, without raising rates of reinfarction or stent thrombosis in STEMI patients.
- - A meta-analysis of six trials involving over 15,000 patients found that while bivalirudin reduced overall and cardiac mortality and major bleeding, it was associated with higher rates of reinfarction and stent thrombosis compared to heparin.
- - When specifically looking at a subset of trials similar to the BRIGHT-4 approach, bivalirudin also showed a decrease in 30-day mortality and major bleeding, with comparable rates of reinfar
Bivalirudin versus heparin in patients with or without bail-out GPI use: a pre-specified subgroup analysis from the BRIGHT-4 trial.
BMC Med
September 2024
Icahn School of Medicine at Mount Sinai, Zena and Michael A Wiener Cardiovascular Institute, New York, NY, USA.
Article Synopsis
- The study looked at two medicines, bivalirudin and heparin, to see which one is safer and better for patients with a serious heart problem called STEMI who are getting a treatment called PCI.
- Many patients didn't use a certain type of medicine (GPI) during the treatment, and those on bivalirudin had better results with fewer deaths and less bleeding.
- However, for those who needed the GPI medicine, there weren't big differences in the results between the two treatments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!